NCT00711880 - A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia. | Biotech Hunter

Enrollment

125

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

March 31, 2004

Study Completion Date

March 31, 2004

Conditions

PainPeripheral Neuropathy

Interventions

DRUG

Sativex®

containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours

DRUG

Placebo

containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.

Trial Locations (1)

L9 7LJ

Clinical Trials Unit, The Walton Centre, Fazakerley